1. Home
  2. SIBN vs FULC Comparison

SIBN vs FULC Comparison

Compare SIBN & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SI-BONE Inc.

SIBN

SI-BONE Inc.

HOLD

Current Price

$13.30

Market Cap

622.3M

Sector

Health Care

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$7.12

Market Cap

535.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SIBN
FULC
Founded
2008
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
622.3M
535.5M
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
SIBN
FULC
Price
$13.30
$7.12
Analyst Decision
Strong Buy
Buy
Analyst Count
8
8
Target Price
$23.88
$16.38
AVG Volume (30 Days)
614.3K
721.5K
Earning Date
05-11-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
41.33
N/A
EPS
N/A
N/A
Revenue
$67,301,000.00
N/A
Revenue This Year
$16.95
N/A
Revenue Next Year
$14.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.53
N/A
52 Week Low
$11.80
$4.78
52 Week High
$21.89
$15.74

Technical Indicators

Market Signals
Indicator
SIBN
FULC
Relative Strength Index (RSI) 50.04 40.86
Support Level $12.15 $6.39
Resistance Level $13.87 $7.09
Average True Range (ATR) 0.72 0.51
MACD -0.05 -0.06
Stochastic Oscillator 51.80 12.42

Price Performance

Historical Comparison
SIBN
FULC

About SIBN SI-BONE Inc.

SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: